Veltassa

Galencia's Bid For Relypsa Is 'Reasonable,' Another Bidder 'Unlikely'

'Steady Growth' For Relypsa's Veltassa Launch

What's The Market Potential For Relypsa Now That AstraZeneca's ZS-9 Is Indefinitely On Hold?

'Steady Growth' For Relypsa's Veltassa Launch

What's The Market Potential For Relypsa Now That AstraZeneca's ZS-9 Is Indefinitely On Hold?

BTIG Still Buying Relypsa As May Prescription Trends Show Steady Veltassa Increases

StreetSweeper On Relypsa: 8 Reasons 'We Wouldn't Run Away & Join This Circus'

BTIG Still Buying Relypsa As May Prescription Trends Show Steady Veltassa Increases

StreetSweeper On Relypsa: 8 Reasons 'We Wouldn't Run Away & Join This Circus'

Relypsa Surges 30% Following Setback From Rival AstraZeneca

Brean Thinks Relypsa's Veltassa Sales Were 'Solid, But Not Impressive'

Veltassa Recent News

BTIG Cuts Veltassa Estimates, Relypsa's Price Target To $35

Mizuho Downgrades Relypsa, Says Near-Term Takeout 'Unlikely'

Morgan Stanley's Berens Highlights Greater Payor Pushback For Relypsa's Veltassa

Cantor: Relypsa Sale Makes Sense

Brean Initiates Relypsa With Buy Rating, $26 Target

Cowen Analysts Happy About Relypsa-Veltassa Launch, Say These Four Things Are Coming

Relypsa Up 10% Following Encouraging Phase 1 Study Results

EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'

Relypsa Plunges After Veltassa FDA Approval; Wedbush Says 'Misunderstanding' Creates Buying Opportunity